Among active 13F managers last quarter, 1 opened and 2 added, while 2 reduced; the largest holder to move was Aristides Capital LLC (+0.0%). Over the last 180 days, 3 insiders bought and none sold, a net +$19K in open-market trades.
Funds lean in and no leg opposes.
12 tracked 13F filers disclose a position in DXR as of the latest SEC 13F filings, a combined $1.7M in reported value. Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| # | Fund | Shares | Position value | Last move | As of | History |
|---|---|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 49K | $496K | ▲+1.1% Added · +551 sh | Q2 2026 | |
| 2 | Aristides Capital LLC | 42K | $429K | ▼~0% Reduced · −3 sh | Q2 2026 | |
| 3 | Renaissance Technologies LLC | 28K | $271K | ▼−0.7% Reduced · −210 sh | Q1 2026 | |
| 4 | Susquehanna International Group, LLP | 14K | $133K | ▲New +14K sh | Q1 2026 | |
| 5 | Nano Cap New Millennium Growth Fund L P | 13K | $129K | —Held | Q2 2026 | |
| 6 | Crescent Grove Advisors, LLC | 12K | $128K | ▲+16% Added · +2K sh | Q2 2026 | |
| 7 | SBI Securities Co., Ltd. | 3K | $32K | ▲+0.1% Added · +3 sh | Q2 2026 | |
| 8 | Morgan Stanley | 3K | $30K | ▼−4.6% Reduced · −150 sh | Q1 2026 | |
| 9 | Vanguard Fiduciary Trust Co | 1K | $11K | —Held | Q2 2026 | |
| 10 | Osaic Holdings, Inc. | 500 | $5K | —Held | Q1 2026 | |
| 11 | Tower Research Capital LLC (TRC) | 109 | $1K | ▲New +109 sh | Q1 2026 | |
| 12 | JPMorgan Chase & Co | 1 | $10 | ▼−80% Reduced · −4 sh | Q1 2026 |
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
Last quarter, 1 fund opened a new position in DXR and 2 added to an existing one, while 2 reduced. Based on 13F filings from active, signal-eligible managers (passive index funds and other mechanical holders are excluded from this count).
| Company | Co-held by | Their position there |
|---|---|---|
| Alphabet Inc-CL AGOOGL | 5 funds | $332.1M |
| Visa Inc-Class A SharesV | 5 funds | $251.4M |
| Mercadolibre IncMELI | 5 funds | $216.2M |
| Zoom Communications IncZM | 5 funds | $202.9M |
| Microsoft CorpMSFT | 5 funds | $184.6M |
| Servicenow IncNOW | 5 funds | $139.2M |
| Toast Inc-Class ATOST | 5 funds | $123.5M |
| Rio Tinto PLC-Spon ADRRIO | 5 funds | $104.9M |
| Pan American Silver CorpPAAS | 5 funds | $82.7M |
| Ishares Biotechnology ETFIBB | 5 funds | $18.6M |
| Richardson Elec LtdRELL | 5 funds | $4.6M |
| Xtant Medical Holdings IncXTNT | 5 funds | $897K |
Ranked by how many of DXR's tracked holders also hold each name. The last column is those co-holders' combined reported position in that name, not in DXR.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Apr 8, 2026 | Feldschuh Michael Richard | Chief Executive Officer, Director | Buy (P) | 1K | $9K |
| Mar 31, 2026 | Michel Robert J | Chief Financial Officer | Buy (P) | 1K | $10K |
| Mar 20, 2026 | Jefferies John | Chief Medical Officer | Buy (P) 2 lots, same day | 6K | $0 |
| Dec 9, 2025 | Michel Robert J | Chief Financial Officer | Buy (P) | 3K | $0 |
| Dec 9, 2025 | Feldschuh Jonathan Adam | Chief Scientific Officer, Director | Buy (P) | 18K | $0 |
| Nov 12, 2025 | Jefferies John | Chief Medical Officer | Buy (P) | 2K | $0 |
| Apr 4, 2025 | Feldschuh Michael Richard | Chief Executive Officer, Director | Buy (P) | 2K | $16K |
| Mar 10, 2025 | Michel Robert J | Chief Financial Officer | Buy (P) | 1K | $8K |
| Dec 6, 2024 | Feldschuh Jonathan Adam | Chief Scientific Officer, Director | Buy (P) | 32K | $0 |
| Dec 6, 2024 | Feldschuh Michael Richard | Chief Executive Officer, Director | Buy (P) | 45K | $0 |
| Mar 27, 2024 | Michel Robert J | Chief Financial Officer | Buy (P) | 750 | $7K |
| Mar 26, 2024 | Feldschuh Michael Richard | Chief Executive Office, Director | Buy (P) | 1K | $8K |
One row per insider, day and transaction code; shares and value are summed across the lots. Every lot is on the full insider page and in the filing.
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 3 | 4 | – |
Insiders Form 4 open-market | 3 | 0 | +$19K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for DXR
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/DXR/capital-change-brief"
Use Arkolith's capital_change_brief for DXR. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + end-of-day price history + the live filing stream, joined for DXR. Filings are public domain, sourced to SEC EDGAR; price series derived from end-of-day closes.